W
Wenbo Xu
Researcher at Chinese Center for Disease Control and Prevention
Publications - 394
Citations - 43545
Wenbo Xu is an academic researcher from Chinese Center for Disease Control and Prevention. The author has contributed to research in topics: Medicine & Outbreak. The author has an hindex of 45, co-authored 330 publications receiving 31929 citations. Previous affiliations of Wenbo Xu include Yunnan University & Centers for Disease Control and Prevention.
Papers
More filters
Journal ArticleDOI
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
Na Zhu,Dingyu Zhang,Wenling Wang,Xingwang Li,Bo Yang,Jingdong Song,Xiang Zhao,Baoying Huang,Weifeng Shi,Roujian Lu,Peihua Niu,Faxian Zhan,Xuejun Ma,Dayan Wang,Wenbo Xu,Wenbo Xu,Guizhen Wu,George F. Gao,Wenjie Tan +18 more
TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Roujian Lu,Xiang Zhao,Juan Li,Peihua Niu,Bo Yang,Honglong Wu,Wenling Wang,Hao Song,Baoying Huang,Na Zhu,Yuhai Bi,Xuejun Ma,Faxian Zhan,Liang Wang,Tao Hu,Hong Zhou,Zhenhong Hu,Weimin Zhou,Li Zhao,Jing Chen,Yao Meng,Ji Wang,Yang Lin,Jianying Yuan,Zhihao Xie,Jinmin Ma,William J. Liu,Dayan Wang,Wenbo Xu,Edward C. Holmes,George F. Gao,George F. Gao,Guizhen Wu,Weijun Chen,Weifeng Shi,Wenjie Tan,Wenjie Tan +36 more
TL;DR: The phylogenetic analysis suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.
Journal ArticleDOI
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Shengli Xia,Yuntao Zhang,Y. Wang,Hui Wang,Yunkai Yang,George F. Gao,Wenjie Tan,Guizhen Wu,Miao Xu,Zhiyong Lou,Weijin Huang,Wenbo Xu,Baoying Huang,Huijuan Wang,Wei Wang,Wei Zhang,Na Li,Zhiqiang Xie,Ling Ding,Wangyang You,Yuxiu Zhao,Xuqin Yang,Yang Liu,Qian Wang,Lili Huang,Yongli Yang,Guangxue Xu,Bojian Luo,Wenling Wang,Peipei Liu,Wanshen Guo,Xiaoming Yang +31 more
TL;DR: The primary outcomes were safety and tolerability and immunogenicity, assessed as the neutralising antibody responses against infectious SARS-CoV-2, and no serious adverse event was reported within 28 days post vaccination.
Journal ArticleDOI
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
Hui Wang,Yuntao Zhang,Baoying Huang,Wei Deng,Yaru Quan,Wenling Wang,Wenbo Xu,Yuxiu Zhao,Na Li,Jin Zhang,Hongyang Liang,Linlin Bao,Yanfeng Xu,Ling Ding,Weimin Zhou,Hong Gao,Jiangning Liu,Peihua Niu,Li Zhao,Wei Zhen,Hui Fu,Yu Shouzhi,Zhang Zhengli,Guangxue Xu,Changgui Li,Zhiyong Lou,Miao Xu,Chuan Qin,Guizhen Wu,George F. Gao,Wenjie Tan,Xiaoming Yang +31 more
TL;DR: Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection.